Trial · NCT03033108

Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

NCT03033108, Phase 2, Completed, Kubota Vision Inc.; results first posted 2021-04-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease. Trials, record NCT03033108. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03033108

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
NCT number: NCT03033108
Status: Completed
Phases: Phase 2
Enrollment: 23 participants, actual
Lead sponsor: Kubota Vision Inc.
Conditions: Stargardt Disease, Macular Atrophy
Interventions: Emixustat
First posted: 2017-01-26
Last updated: 2021-05-19
Results first posted: 2021-04-27
Limitations and caveats: Small sample size and inherent, significant intersubject and intrasubject variability observed in electroretinography.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram	Baseline and 1 month	Percent suppression compared to baseline of rod b-wave amplitude recovery after a photobleaching light.
Secondary	Percentage of Subjects With Adverse Events, by Severity and Seriousness	1 month	Assessment of safety profile

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram	Baseline and 1 month	Subjects with evaluable ERGs at both Baseline and Month 1	percent suppression	MEDIAN
SECONDARY	Percentage of Subjects With Adverse Events, by Severity and Seriousness	1 month		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram	Emixustat Dose 1		-12.23	Full Range -41.0 to 54.7	percent suppression
Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram	Emixustat Dose 2		68.00	Full Range 1.0 to 91.5	percent suppression
Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram	Emixustat Dose 3		96.69	Full Range 64.9 to 100.0	percent suppression
Percentage of Subjects With Adverse Events, by Severity and Seriousness	Emixustat Dose 1	Subjects with 1 or more adverse events	6		Participants
Percentage of Subjects With Adverse Events, by Severity and Seriousness	Emixustat Dose 2	Subjects with 1 or more adverse events	8		Participants
Percentage of Subjects With Adverse Events, by Severity and Seriousness	Emixustat Dose 3	Subjects with 1 or more adverse events	6		Participants
Percentage of Subjects With Adverse Events, by Severity and Seriousness	Emixustat Dose 1	Subjects with 1 or more mild adverse events	5		Participants
Percentage of Subjects With Adverse Events, by Severity and Seriousness	Emixustat Dose 2	Subjects with 1 or more mild adverse events	5		Participants
Percentage of Subjects With Adverse Events, by Severity and Seriousness	Emixustat Dose 3	Subjects with 1 or more mild adverse events	4		Participants
Percentage of Subjects With Adverse Events, by Severity and Seriousness	Emixustat Dose 1	Subjects with 1 or more moderate adverse events	1		Participants

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Emixustat Dose 1	7
Overall Study	STARTED	Emixustat Dose 2	9
Overall Study	STARTED	Emixustat Dose 3	7
Overall Study	COMPLETED	Emixustat Dose 1	7
Overall Study	COMPLETED	Emixustat Dose 2	8
Overall Study	COMPLETED	Emixustat Dose 3	7
Overall Study	NOT COMPLETED	Emixustat Dose 1	0
Overall Study	NOT COMPLETED	Emixustat Dose 2	1
Overall Study	NOT COMPLETED	Emixustat Dose 3	0

Source ClinicalTrials.gov

Adverse events69

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Delayed Dark Adaptation	Eye disorders	Emixustat Dose 1	1	7
other	Delayed Dark Adaptation	Eye disorders	Emixustat Dose 2	6	9
other	Delayed Dark Adaptation	Eye disorders	Emixustat Dose 3	4	7
other	Erythropsia	Eye disorders	Emixustat Dose 1	1	7
other	Erythropsia	Eye disorders	Emixustat Dose 2	3	9
other	Erythropsia	Eye disorders	Emixustat Dose 3	1	7
other	Vision blurred	Eye disorders	Emixustat Dose 1	2	7
other	Vision blurred	Eye disorders	Emixustat Dose 2	1	9
other	Vision blurred	Eye disorders	Emixustat Dose 3	1	7
other	Photophobia	Eye disorders	Emixustat Dose 1	1	7

1 to 10 of 69Source ClinicalTrials.gov

See all 69 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Emixustat Dose 1	0	7
Total, all-cause mortality	Emixustat Dose 2	0	9
Total, all-cause mortality	Emixustat Dose 3	0	7
Total, other adverse events	Emixustat Dose 1	6	7
Total, other adverse events	Emixustat Dose 2	8	9
Total, other adverse events	Emixustat Dose 3	7	7
Total, serious adverse events	Emixustat Dose 1	0	7
Total, serious adverse events	Emixustat Dose 2	0	9
Total, serious adverse events	Emixustat Dose 3	0	7

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33214244	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03033108

GET https://conductscience.org/api/trials/v1/NCT03033108/events?page=2

API reference For AI assistants